Skip to main content

Table 1 Socio-demographic and Clinical characteristics of the studied Cohort

From: Correlation between initial tumour volume and treatment duration on Dabrafenib: observation study of subjects with BRAF mutant melanoma on the BRF112680 trial

Variable

Category

n = 10

Age Group

Mean ± SD

57.63 ± 16.2

Median (IQR)

61.5 (20)

Sex

Male

8 (80%)

Female

2 (20%)

ECOG at Baseline

0

4 (40%)

1

6 (60%)

Co-morbidity*

Positive

6 (60%)

Negative

4 (40%)

No. Involved Organs

1

4 (40%)

>  1

6 (60%)

TV (cc)

Mean ± SD

111.50 ± 59.6

Median (IQR)

27.5 (80)

LDH (120–250 Unit/litre)

Mean ± SD

290.38 ± 92.8

Median (IQR)

258.5 (114)

RECIST Response

PR

3 (30%)

Stable

2 (20%)

PD

5 (50%)

Survival data

Dead

3 (30%)

Alive

7 (70%)

  1. * Co-morbidities included diabetes mellitus (DM), hypertension, ischemic/valvular heart disease, glaucoma, benign prostatic hyperplasia
  2. ECOG European Cooperative Oncology Group, IQR interquartile range, LDH lactate dehydrogenase, PR partial remission, PD progressive disease, RECIST response criteria in solid tumors, SD standard deviation, TV tumor volume